Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268747 | 0.93 | CPB2 (1.00) | CPB2CPB1 | |
| SCHEMBL3839535 | 0.93 | CPB2 (1.00) | CPB2CPB1 | |
| SCHEMBL7202306 | 0.88 | CPB2 (1.00) | CPB2CPB1 | |
| SCHEMBL3839300 | 0.88 | CPB2 (1.00) | CPB2CPB1 | |
| SCHEMBL3844062 | 0.86 | CPB2 (0.79) | CPB2CPB1 | |
| SCHEMBL5663299 | 0.84 | CPB2 (0.68) | CPB2CPB1 | |
| SCHEMBL3838506 | 0.83 | CPB2 (1.00) | CPB2CPB1 | |
| SCHEMBL3841445 | 0.83 | CPB2 (0.77) | CPB2CPB1 | |
| SCHEMBL3843789 | 0.83 | CPB2 (0.73) | CPB2CPB1 | |
| SCHEMBL5665030 | 0.80 | CPB2 (0.72) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051384-A1 | STABILISED PHARMACEUTICAL COMPOSITIONS | PFIZER LIMITED (GB) | 2005-06-09 | — | — | WO | claimed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | claimed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | claimed |
| EP-1311488-B1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LTD (GB) | 2009-11-04 | — | — | EP | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| WO-2005051384-A1 | STABILISED PHARMACEUTICAL COMPOSITIONS | PFIZER LIMITED (GB) | 2005-06-09 | — | — | WO | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| EP-1311488-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | Pfizer Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
| WO-2002014285-A1 | SUBSTITUTED IMIDAZOLES AS TAFIA INHIBITORS | PFIZER LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | CPB2 234/4885CPB1 168/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | CPB2 167/4885CPB1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.